New analysis of LIFE trial shows reduction of new-onset atrial fibrillation with losartan

Br J Cardiol 2005;12:268-9 Leave a comment
Click any image to enlarge
Authors:

A new analysis of the LIFE study has shown that losartan can reduce new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. General practitioner Brian Crichton summarises this new analysis and explains how losartan might achieve these effects.

Advertisement
Heart failure - BJC Learning programme
For healthcare professionals only

THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT